Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 522-525

  Dangsuwan, Penkae ^a   Manchana, Tarinee ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Anemia; Blood transfusion; Gynecologic cancer; Intravenous iron; Quality of life

Indexed keywords

CARBOPLATIN; DOCETAXEL; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; HEMOGLOBIN; PACLITAXEL;

ADULT; ANEMIA; ARTICLE; BLOATING; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ERYTHROCYTE TRANSFUSION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; IRON THERAPY; MYALGIA; NAUSEA AND VOMITING; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ENDOMETRIAL NEOPLASMS; ERYTHROCYTE TRANSFUSION; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS; YOUNG ADULT;

EID: 75749138424     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.004     Document Type: Article

References (22)

1. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin. Oncol. 25 (1998) 43-46
2. Clarke H., and Pallister C.J. The impact of anaemia on outcome in cancer. Clin. Lab. Haematol. 27 (2005) 1-13
3. Birgegard G., Aapro M.S., Bokemeyer C., Dicato M., Drings P., Hornedo J., et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68 Suppl. 1 (2005) 3-11
4. Weiss G., and Goodnough L.T. Anemia of chronic disease. N. Engl. J. Med. 352 (2005) 1011-1023
5. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91 (1999) 1616-1634
6. Auerbach M. Should intravenous iron be the standard of care in oncology?. J. Clin. Oncol. 26 (2008) 1579-1581
7. Wilson J., Yao G.L., Raftery J., Bohlius J., Brunskill S., Sandercock J., et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 11 (2007) 1-202 iii-iv
8. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
9. Arcasoy M.O. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin. Cancer Res. 14 (2008) 4685-4690
10. Yellen S.B., Cella D.F., Webster K., Blendowski C., and Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain Symptom Manage 13 (1997) 63-74
11. Ludwig H., Van Belle S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40 (2004) 2293-2306
12. Wojtukiewicz M.Z., Sierko E., Rybaltowski M., Filipczyk-Cisarz E., Staroslawska E., Tujakowski J., et al. The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. Int. J. Hematol. 89 (2009) 276-284
13. Eichbaum M.H., Weiss L.M., Bruckner T., Schneeweiss A., Sinn H.P., Gebauer G., et al. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med. Sci. Monit. 15 (2009) CR156-63
14. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 (2009) 1532-1542
15. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin. Med. Res. 6 (2008) 93-102
16. Hedenus M., and Birgegard G. The role of iron supplementation during epoietin treatment for cancer-related anemia. Med. Oncol. 26 (2009) 105-115
17. Candelaria M., Cetina L., and Duenas-Gonzalez A. Anemia in cervical cancer patients: implications for iron supplementation therapy. Med. Oncol. 22 (2005) 161-168
18. Kim Y.T., Kim S.W., Yoon B.S., Cho H.J., Nahm E.J., Kim S.H., et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol. Oncol. 105 (2007) 199-204
19. Auerbach M., Ballard H., and Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 369 (2007) 1502-1504
20. Bailie G.R., Clark J.A., Lane C.E., and Lane P.L. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol. Dial. Transplant. 20 (2005) 1443-1449
21. Lyseng-Williamson K.A., and Keating G.M. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 69 (2009) 739-756
22. Roungrong J., Teerawattananon Y., and Chaikledkaew U. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand. J. Med. Assoc. Thai. 91 Suppl. 2 (2008) S119-S125